The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

Phase 4

Withdrawn

Brief Summary: It is well known that the use of loop diuretics in acute setting may decrease glomerular filtration rate (GFR) and increase serum creatinine leading to renal dysfunction. Loop diuretic induced elevation in serum creatinine can lead to increase in length of hospital stay and possibly morbidity. Previous studies have suggested that tolvaptan unlike aggressive loop diuretic therapy may not activate neurohormonal system nor decrease renal blood flow. These properties may make tolvaptan a useful addition to diuretic therapy to prevent renal dysfunction in high-risk patients. Therefore the primary objective of this study is to determine if the use of tolvaptan in combination with diuretic therapy may prevent development of renal dysfunction in high risk patients with heart failure.

Hypothesis: Administration of tolvaptan in combination with continuous loop diuretic therapy in acutely decompensated heart failure patients at high risk for developing diuretic induced renal dysfunction will have a lower proportion of patients increasing their serum creatinine \> 0.3 mg/dL within a 96 hour time frame as compared to patients just receiving standard of care continuous infusion diuretic.

Recruitment & Eligibility

Inclusion Criteria

≥ 18 years old
Prior clinical diagnosis of systolic heart failure (EF < 40% within the past 18 months) with daily home use of oral loop diuretic for at least one month.
Daily oral dose of furosemide ≥ 40 mg and ≤ 240 mg (or equivalent)
Identified within 24 hours of hospital admission
Heart failure defined by at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography)
Anticipated need for IV loop diuretics for at least 48 hours
Likely requires daily net urine output in the range of 1-3 L/day for over a 72-96 hour time period.
Albumin level < 3.5 g/dL
Willingness to provide informed consent

Exclusion Criteria

Received or planned IV vasoactive treatment (inotropes, vasodilators) or ultra-filtration therapy for heart failure
BNP < 250 ng/ml or NT-proBNP < 1000 mg/ml (if drawn for clinical purposes)
Systolic BP < 90 mmHg
Serum creatinine > 3.0 mg/dl at baseline or renal replacement therapy or creatinine clearances < 10 mL/min
Serum sodium > 145 mEq/L
Acute coronary syndrome within 4 weeks
Anticipated need for coronary angiography or other procedures requiring IV contrast.
Patients receiving any of the following drugs: clarithromycin, ketoconazole, itraconazole,ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin, erythromycin, fluconazole, aprepitant, diltiazem, verapamil, cyclosporine, and grapefruit juice.
Pregnant or nursing patients.

Arm && Interventions

Group	Intervention	Description
Placebo	placebo	Placebo x 3 days and standard of care continuous infusion diuretic
Tolvaptan Arm	Tolvaptan	Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing: Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr

Primary Outcome Measures

Name	Time	Method
Renal dysfunction	96 hours	Increase in serum creatinine \> 0.3 mg/dL within a 96 hours from enrollment

Secondary Outcome Measures

Name	Time	Method
Weight	24, 78, 72, 96	Change in weight over 24, 48, 72, and 96 hours
Urine output	24, 48, 72, 96	Net urine output over 24, 48, 72, and 96 hours
Hospitalization length of stay	10

Locations (1): University of Michigan Health Systems
🇺🇸
Ann Arbor, Michigan, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial